Trial Profile
Clinical phase III study of YP-18 for febrile neutropenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 30 Jun 2015 New trial record
- 26 Jun 2015 As per a Taiho Pharmaceutical media release, this trial is one of the pivotal trials on which the MHLW Japan approval of piperacillin/tazobactam for use in Febrile Neutropenia is based upon.